Results from the pivotal PHOTON and PULSAR trials highlighted the success of 8-mg aflibercept every 12 or 16 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback